Scientific and Clinical Advisors

Dr. Corte, BSc(Med), MBBS, FRACP, PhD, is a Consultant Respiratory Physician and Director of Interstitial Lung Disease in the Department of Respiratory Medicine at Royal Prince Alfred Hospital, and Clinical Professor at the University of Sydney. She is Chief Investigator on the Centre of Research Excellence for Pulmonary Fibrosis, which strives to improve and extend the lives of patients living with pulmonary fibrosis through the development of a comprehensive and integrated program of basic and clinical research and education across Australia.  She is the founding Chair of the Steering Committee for the Australian Idiopathic Pulmonary Fibrosis Registry, the Australasian Interstitial Lung Disease Registry, and leads her clinical and translational Pulmonary Fibrosis research group at the University of Sydney.

Professor Corte trained in respiratory medicine at the University of New South Wales in Sydney, Australia. She served as Clinical Fellow in Interstitial Lung Disease at the Royal Brompton Hospital in London with Professor Athol Wells, and earned a doctor of philosophy degree in the identification of pulmonary vascular dysfunction in interstitial lung disease.

Dr. Glaspole is the head of the Alfred Hospital interstitial lung disease clinic and an adjunct clinical associate professor within the Monash University Faculty of Medicine. He is the chair of the Pulmonary Fibrosis Australasian Clinical Trials Network, and an associate investigator in the Centre for Research Excellence in Pulmonary Fibrosis.

Dr. Maher has spent the last 20 years specializing in the management of all forms of pulmonary fibrosis and orphan interstitial lung diseases. He previously ran the ILD unit at Royal Brompton Hospital, London. Since June 2020 he has been Director of ILD at Keck Medicine of University of Southern California in Los Angeles. He remains Professor of Interstitial Lung Disease at Imperial College London. His research interests include; biomarker discovery (including spirometry and physiological biomarkers), the lung microbiome and host immune response in the pathogenesis of IPF and clinical trials in interstitial lung disease. He has been involved in >80 trials in fibrotic lung disease from phase 1b through to phase 4 and including those assessing IPF, sarcoidosis, scleroderma, rheumatoid arthritis and inflammatory myositis. He is an associate editor for American Journal of Respiratory and Critical Care Medicine and European Respiratory Review and is on the Editorial Board of Lancet Respiratory Medicine. He has authored over 380 papers and book chapters on pulmonary fibrosis.

Dr. Molyneaux is a professor of Interstitial Lung disease at Imperial College London. He is the Asthma and Lung UK Chair of Respiratory Research. He is a consultant in Interstitial lung disease and the director of the NIHR Cardiorespiratory Clinical research facility at the Royal Brompton Hospital. He runs an active clinical and translational research program that oversees a team of basic scientists and clinical trial research staff.

Dr. Abida is Director of Translational Research in Prostate Cancer, Associate Member in the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center and Associate Professor of Medicine at Weill Cornell Medical College. His research focuses on the genomics of prostate cancer and on the development of molecularly-guided therapies in prostate cancer and other solid tumors. He leads analysis of MSKCC’s prostate cancer clinical-genomic dataset and is involved in multiple international prostate cancer genomics efforts. He also leads clinical trials investigating DNA repair and epigenetic-targeting agents in prostate cancer and other malignancies. One of these trials resulted in the first FDA approval of a PARP inhibitor, rucaparib, for the treatment of prostate cancer. Dr. Abida obtained his M.D. and Ph.D. degrees at Columbia University and completed internal medicine residency training at the Hospital of the University of Pennsylvania. He completed his medical oncology fellowship training at Memorial Sloan Kettering Cancer Center, where he studied mechanisms of androgen receptor activity in the laboratory of Dr. Charles L. Sawyers, and served as Chief Fellow in hematology/oncology. He has received funding from the NCI, Department of Defense CDMRP and the Prostate Cancer Foundation.

Professor de Bono is Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust. He is also Director of the Drug Development Unit, overseeing the conduct of phase I trials, with a particular interest in innovative trial designs, circulating biomarkers and prostate cancer. An international expert in the development of novel anticancer therapies against adult cancers, Professor de Bono leads the Prostate Cancer Targeted Therapy Group and the Cancer Biomarkers group at the ICR. He graduated from the University of Glasgow medical school as a Member of the Royal College of Physicians. He was subsequently awarded a four-year Cancer Research Campaign Clinical Fellowship, which allowed him to pursue a PhD. Following his PhD, he trained in medical oncology and was awarded a Master of Science in Cancer Science from the University of Glasgow.

Dr. Siwen Hu-Lieskovan is an Associate Professor of Medicine, and Director of Solid Tumor Immunotherapy at the Huntsman Cancer Institute (HCI), University of Utah. She received her Hematology/Oncology Fellowship training at UCLA and held a faculty position there after fellowship prior to recruitment to HCI. She is a board-certified oncologist with clinical focus on melanoma/skin cancers and early phase testing of cancer immunotherapies in solid tumors. She is experienced with protocol development and conduct of immunotherapy-based clinical trials, and has been a principal investigator of industry-, investigator- and cooperative group-initiated clinical trials testing immune checkpoint inhibitors, oncolytic viruses, cancer vaccines and other immune-modulatory agents, as well as cell therapy with genetically modified T cells and hematopoietic stem cells. Dr. Hu-Lieskovan chairs the SWOG Immunotherapeutics Committee. She is a study chair and translational lead of several cross-NCTN protocols initiated by SWOG, including the immunoMATCH trial. She has been a scientific advisor on cancer immunotherapy drug development strategies for the pharmaceutical and biotechnology industry.

Dr. Le is a Professor of Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University in Baltimore, Maryland.  She is a Bloomberg-Kimmel Professor of Cancer Immunotherapy and the Director of Gastrointestinal Clinical Trials.  Dr. Le received her undergraduate degree at Yale University and underwent internal medicine and oncology fellowship training at Johns Hopkins University.  Her research interests include novel approaches to patients with gastrointestinal malignancies.  She helped lead the development of programmed death-1 (PD-1) blockade in tumors with mismatch repair deficiency across disease types which led to the first biomarker selection tissue agnostic FDA approval.  Her primary areas of research and clinical care include pancreatic, colorectal, and mismatch repair deficient cancers.

Professor Aurélien Marabelle is a physician-scientist with expertise in oncology (MD) and immunology (PhD). His clinical practice is dedicated to early phase clinical trials of cancer immunotherapies within the Drug Development Department (DITEP) of Gustave Roussy Cancer Center in France. He leads a translational research laboratory (LRTI) within the INSERM U1015 with a focus on mechanisms of action of immune targeted therapies. He is also the director of the Clinical Investigation Center BIOTHERIS dedicated to intratumoral immunotherapies (INSERM CIC1428). He is a full professor of Clinical Immunology at the University of Paris Saclay. Dr. Marabelle was initially trained as a scientist in the Ecole Normale Supérieure de Lyon and King’s College London and as a clinician at the Léon Bérard Cancer Center in Lyon, France. He did his post-doctoral research fellowship in the laboratory of Professor Ronald Levy at Stanford University, CA on strategies to overcome the resistance to immune checkpoint targeted therapies. Dr. Marabelle is an active member of ESMO, ASCO, AACR, SITC, EATI and is the current vice-president of the French Society for Cancer Immunotherapies (FITC). He has published more than 250 peer-reviewed publications and has a H-index of 69.